Prelude Therapeutics Income Statement (2019-2026) | PRLD

Income Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
3.00M4.00M6.50M5.64M4.58M
Operating items
Research & Development (Quarter)
22.41M22.72M25.18M22.82M21.31M22.89M25.87M21.83M24.97M26.26M30.33M27.41M29.51M29.46M31.62M28.82M25.78M21.71M17.99M13.60M
Selling, General & Administrative (Quarter)
5.51M8.12M7.83M7.47M8.15M7.52M7.52M7.28M7.43M7.12M7.05M6.93M7.66M7.92M6.21M5.79M6.41M5.21M5.00M5.16M
Operating Expenses (Quarter)
27.92M30.84M33.01M30.29M29.46M30.41M33.38M29.11M32.40M33.38M37.38M34.34M37.16M37.38M37.83M34.61M32.19M26.92M22.99M18.76M
Operating Income (Quarter)
-27.92M-30.84M-33.01M-30.29M-29.46M-30.41M-33.38M-29.11M-32.40M-33.38M-37.38M-34.34M-37.16M-34.38M-33.83M-34.61M-32.19M-20.42M-17.35M-14.18M
EBIT (Quarter)
-27.92M-30.84M-33.01M-30.29M-29.46M-30.41M-33.38M-29.11M-32.40M-33.38M-37.38M-34.34M-37.16M-34.38M-33.83M-34.61M-32.19M-20.42M-17.35M-14.18M
Non-operating items
Other Non Operating Income (Quarter)
1.06M0.15M0.17M0.82M2.09M0.45M4.74M1.40M1.97M2.78M4.30M2.91M2.42M2.10M5.10M2.52M0.96M0.69M0.89M3.79M
Net income details
EBT (Quarter)
-159.02M-170.14M-108.38M-41.59M-37.16M-42.51M-144.44M-38.22M-37.80M-35.98M-37.86M-77.64M-79.85M-76.48M-34.36M-57.55M-54.47M-42.02M-18.08M-34.44M
Profit After Tax (Quarter)
-26.86M-30.86M-32.84M-29.46M-27.37M-30.03M-27.97M-27.72M-30.43M-30.61M-32.25M-31.43M-34.74M-32.27M-28.92M-32.11M-31.23M-19.73M-16.42M-10.43M
Income from Continuing Operations (Quarter)
-159.02M-170.14M-108.38M-41.59M-37.16M-42.51M-144.44M-38.22M-37.80M-35.98M-37.86M-77.64M-79.85M-76.48M-34.36M-57.55M-54.47M-42.02M-18.08M-34.44M
Consolidated Net Income (Quarter)
-159.02M-170.14M-108.38M-41.59M-37.16M-42.51M-144.44M-38.22M-37.80M-35.98M-37.86M-77.64M-79.85M-76.48M-34.36M-57.55M-54.47M-42.02M-18.08M-34.44M
Income towards Parent Company (Quarter)
-159.02M-170.14M-108.38M-41.59M-37.16M-42.51M-144.44M-38.22M-37.80M-35.98M-37.86M-77.64M-79.85M-76.48M-34.36M-57.55M-54.47M-42.02M-18.08M-34.44M
Net Income towards Common Stockholders (Quarter)
-159.02M-170.14M-108.38M-41.59M-37.16M-42.51M-144.44M-38.22M-37.80M-35.98M-37.86M-77.64M-79.85M-76.48M-34.36M-57.55M-54.47M-42.02M-18.08M-34.44M
Additional items
EPS (Basic) (Quarter)
-3.45-3.67-2.35-0.88-0.79-0.90-3.05-0.80-0.67-0.53-0.63-1.03-1.05-1.01-0.45-0.76-0.72-0.55-0.23-0.42
EPS (Diluted) (Quarter)
-3.45-3.67-2.35-0.88-0.79-0.90-3.05-0.80-0.67-0.53-0.63-1.03-1.05-1.01-0.45-0.76-0.72-0.55-0.23-0.42
Shares Outstanding (Quarter)
46.06M46.33M46.05M47.07M47.28M47.45M47.37M47.74M56.24M67.64M60.36M75.74M75.76M75.86M75.81M75.99M75.99M76.13M76.96M82.52M
Shares Outstanding (Diluted) (Quarter)
46.06M46.33M46.05M47.07M47.28M47.45M47.37M47.74M56.24M67.64M60.36M75.74M75.76M75.86M75.81M75.99M75.99M76.13M76.96M82.52M
EBITDA (Quarter)
-27.92M-30.84M-33.01M-30.29M-29.46M-30.41M-33.38M-29.11M-32.40M-33.38M-37.38M-34.34M-37.16M-34.38M-33.83M-34.61M-32.19M-20.42M-17.35M-14.18M
Interest Expenses (Quarter)
131.10M139.30M75.37M11.30M7.70M12.10M111.05M9.10M5.40M2.60M0.48M43.29M42.69M42.11M0.53M22.94M22.27M21.60M0.73M20.27M